Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 908 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Edema, Macular Degeneration
Interventions
Ranibizumab
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Lakeland, Florida • Palm Beach Gardens, Florida • Tampa, Florida + 7 more
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
Conditions
Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions
Aflibercept, foselutoclax
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Conditions
Macular Degeneration
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions
Vitamin A Palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Retinal Drusen, Age-related Macular Degeneration, Macular Degeneration
Interventions
Lumega-Z, AREDS2
Dietary Supplement
Lead sponsor
Guardion Health Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Conditions
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Interventions
Ixo-vec
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
12
States / cities
Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more
Conditions
Neovascular Age Related Macular Degeneration
Interventions
iSONEP
Biological
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 2 more
Completed No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Visual Acuity Module.

NCT04169802
Conditions
Age Related Macular Degeneration
Interventions
Retinal Health Monitoring System Visual Acuity Module, Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Conditions
Macular Degeneration, Age-related, Geographic Atrophy
Interventions
BI 771716, Pegcetacoplan, Sham comparator to BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed No phase listed Observational Accepts healthy volunteers

Telemedicine in Age-Related Macular Degeneration

NCT04863391
Conditions
Age Related Macular Degeneration
Interventions
Referrable versus Non Referral AMD diagnostic test
Diagnostic Test
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
34
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
dexamethasone intravitreal implant 0.7 mg
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Macular Degeneration
Interventions
intravitreal injection Lucentis (ranibizumab)
Drug
Lead sponsor
Retina Research Foundation
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Slingerlands, New York
Conditions
Macular Degeneration
Interventions
VEGF Trap Eye
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
33
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more
Conditions
Geographic Atrophy
Interventions
RO7303359
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Mountain View, California • Sacramento, California • Santa Maria, California + 9 more
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
Scott Raymond
Other
Eligibility
50 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Completed No phase listed Observational Accepts healthy volunteers

A Single-Center Pilot Study to Assess Macular Function

NCT01204541
Conditions
Macular Degeneration
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
20 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Macular Edema, Retinal Artery Macroaneurysm
Interventions
aflibercept
Drug
Lead sponsor
Kamal Kishore, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Peoria, Illinois